Clinical Trials
Closed Recruiting
-
METADUR
An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors.
Sponsor: In-House
Principal Investigator: Dr. Lillian Siu
NCT#: NCT02811497
-
PRIMED
Window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative mocetinostat and durvalumab. Eligible Tumour Type(s): squamous cell carcinoma of the oral cavity
Sponsor: In-House
Principal Investigator: Dr. Lillian Siu
NCT#: NCT02993991 -
Role of microbiome as a biomarker in loco-regionally-advanced oropharyngeal squamous cell carcinoma (ROMA)Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
Sponsor: In-house
Principal Investigator: Drs. Lillian Siu and Anna Spreafic
NCT#: N/A -
Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
Sponsor: In-house
Principal Investigator: Dr. Lillian Siu
NCT#: NCT03575598 -
Tumor Immunotherapy and MicrobiomE Analysis Project (TIME)Eligible Tumour Type(s): Metastatic Melanoma
Sponsor: In-house
Principal Investigator: Dr. Marcus Butler
NCT#: N/A -
Role of Microbiome as a Biomarker in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (ROMA LA-OPSCC-2)Eligible Tumour Type(s): Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma
Sponsor: In-house
Principal Investigator: Dr. Anna Spreafico
NCT#: NCT03838601
-
TILs-001-DC
A Phase I Study evaluating the feasibility and safety of infusion of Re-StimulatedAutologous tumor-infiltrating lymphocytes (TILs) followed by low-dose interleukin-2 therapy in patients with platinum resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer
Sponsor: In-House
Principal Investigator: Dr. Marcus Butler
NCT#: NCT01883297
-
TILs-002-MEL
Phase II Study evaluating the infusion of autologous tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with metastatic melanoma.
Sponsor: In-House
Principal Investigator: Dr. Marcus Butler
NCT#: NCT01883323
https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1
Pages
- « first
- ‹ previous
- 1
- 2
- 3